文章基本信息

标题：Longitudinal Predictors of Human Papillomavirus Vaccination Among a National Sample of Adolescent Males
本地全文：下载
作者：Paul L. Reiter ; Annie-Laurie McRee ; Jessica K. Pepper 等
期刊名称：American journal of public health
印刷版ISSN：0090-0036
出版年度：2013
卷号：103
期号：8
页码：1419-1427
DOI：10.2105/AJPH.2012.301189
语种：English
出版社：American Public Health Association
摘要：Objectives. We conducted a longitudinal study to examine human papillomavirus (HPV) vaccine uptake among male adolescents and to identify vaccination predictors. Methods. In fall 2010 and 2011, a national sample of parents with sons aged 11 to 17 years (n = 327) and their sons (n = 228) completed online surveys. We used logistic regression to identify predictors of HPV vaccination that occurred between baseline and follow-up. Results. Only 2% of sons had received any doses of HPV vaccine at baseline, with an increase to 8% by follow-up. About 55% of parents who had ever received a doctor’s recommendation to get their sons HPV vaccine did vaccinate between baseline and follow-up, compared with only 1% of parents without a recommendation. Fathers (odds ratio = 0.29; 95% confidence interval = 0.09, 0.80) and non-Hispanic White parents (odds ratio = 0.29; 95% confidence interval = 0.11, 0.76) were less likely to have vaccinated sons. Willingness to get sons HPV vaccine decreased from baseline to follow-up among parents ( P < .001) and sons ( P = .003). Conclusions. Vaccination against HPV remained low in our study and willingness to vaccinate may be decreasing. Physician recommendation and education about HPV vaccine for males may be key strategies for improving vaccination. Quadrivalent human papillomavirus (HPV) vaccine against types 6, 11, 16, and 18 is approved to protect against genital warts (caused mostly by HPV types 6 and 11 1 ) and anal cancer (caused mostly by HPV types 16 and 18 2 ) in males. 3 About 4% of men in the United States report a previous diagnosis of genital warts, 4 and about 2250 new cases of anal cancer occur annually among males in the United States. 5 Given the high levels of HPV concordance among sexual partners, 6 vaccinating males may also have indirect health benefits for their partners. 7 United States guidelines began including HPV vaccine for males in October 2009. 8 The Advisory Committee on Immunization Practices first provided a permissive recommendation, recommending the 3-dose quadrivalent vaccine series for males aged 9 to 26 years but not making it part of their routine vaccination schedule. 8 In October 2011, the Advisory Committee on Immunization Practices updated its stance on HPV vaccine for males and recommended routine vaccination of boys aged 11 to 12 years with catch-up vaccination for males aged 13 to 21 years. 9 The updated recommendation continues to allow HPV vaccine to be given to males aged as young as 9 years and up to 26 years. 9 Although numerous studies have examined HPV vaccine uptake among females, 10 data on HPV vaccine uptake among males are sparse. Despite mostly encouraging early levels of parental acceptability of the vaccine for males, 11–13 initial estimates found that only about 2% of male adolescents in the United States had received any doses of HPV vaccine by the end of 2010. 14,15 Recent data suggest that this increased to about 8% by the end of 2011. 16 We are not aware of any studies that have examined predictors of vaccine uptake among males. Our study addresses several important gaps in the existing literature. We provide the first longitudinal examination of HPV vaccination among males and identify predictors of vaccine uptake. In doing so, we used data from both parents and their adolescent sons because many adolescents are involved in vaccination decisions. 17 We also examined longitudinal changes in vaccine acceptability among parents and sons and parents’ reasons for not getting their sons HPV vaccine, because these data may provide valuable insight about future HPV vaccine uptake among males.